arvinas
-
Pfizer commits $1B to Arvinas for share of protein degrading breast cancer drug
Arvinas’ early clinical data for its targeted protein degradation drug for breast cancer drew partnering interest from several companies. Pfizer beat them all with a deal that pays the biotech $1 billion to share in the development and commercialization of this therapy.
-
Pfizer and Arvinas sign $830M drug development deal that target proteins causing disease
Pfizer is paying big bucks for yet-to-be-discovered small molecule drugs that can break down harmful proteins in diseases such as cancer and Alzheimer’s.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Arvinas raises $41.6M for protein degradation drugs
Yale spinout Arvinas just raised $41.6 million for its platform of protein degradation drugs – a different mechanism than the standard protein inhibition drugs on the market.